BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jun 2018: Trial registered, NCT03549871
  2. 25 Jul 2018: Trial started, NCT03549871

The trials

NCT03549871: A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

State
Completed
Phase
Phase 3
People
80 taking part
Started
25 Jul 2018
Primary completion
20 Jan 2022
Arms
Fitusiran
Results
Posted on the registry
  1. 8 Jun 2018: Trial registered
  2. 25 Jul 2018: Trial started
  3. 25 Mar 2022: Trial completed
  4. 6 Feb 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.